- Home
- AGIO vs BLX Comparison
AGIO vs BLX Comparison
Compare AGIO & BLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | BLX |
|---|---|---|
| Founded | 2007 | 1977 |
| Country | United States | Panama |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2013 | 1997 |
Fundamental Metrics
Financial Performance| Metric | AGIO | BLX |
|---|---|---|
| Price | $37.22 | $55.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $46.00 | ★ $65.90 |
| AVG Volume (30 Days) | ★ 1.0M | 129.0K |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 4.93% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $229.47 | $10.52 |
| Revenue Next Year | $94.99 | $10.12 |
| P/E Ratio | ★ N/A | $8.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $38.41 |
| 52 Week High | $46.00 | $63.20 |
Technical Indicators
Market Signals| Indicator | AGIO | BLX |
|---|---|---|
| Relative Strength Index (RSI) | 67.97 | 49.56 |
| Support Level | $32.17 | $52.85 |
| Resistance Level | $44.09 | $56.04 |
| Average True Range (ATR) | 1.34 | 1.29 |
| MACD | 0.66 | 0.08 |
| Stochastic Oscillator | 98.33 | 48.68 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Bladex Inc is a Panama-based bank focused on providing financial solutions to financial institutions and corporations throughout Panama.